PriceTargets.com logo

NASDAQ:ITRM - Iterum Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.70
  • Forecasted Upside: 211.66 %
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.22 As of 05/27/2022 05:00 PM ET
▼ -0.01 (-4.29%)

This chart shows the closing price for ITRM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Iterum Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ITRM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ITRM

Analyst Price Target is $0.70
▲ +211.66% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Iterum Therapeutics in the last 3 months. The average price target is $0.70, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 211.66% upside from the last price of $0.22.

This chart shows the closing price for ITRM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Iterum Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
6/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
8/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
2/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/27/2021GabelliUpgradeSell ➝ Hold$0.70High
7/26/2021HC WainwrightDowngradeBuy ➝ Neutral$0.69N/A
7/2/2021G.ResearchDowngradeHold ➝ SellN/A
5/28/2021G.ResearchUpgradeSell ➝ HoldN/A
5/28/2021GabelliUpgradeSell ➝ HoldHigh
3/15/2021HC WainwrightUpgradeNeutral ➝ Buy$2.50Medium
1/26/2021HC WainwrightReiterated RatingHoldHigh
12/24/2020HC WainwrightReiterated RatingHoldN/A
10/1/2020SVB LeerinkBoost Price TargetMarket Perform$1.00 ➝ $1.50High
8/10/2020Royal Bank of CanadaReiterated RatingHold$2.00Medium
6/16/2020HC WainwrightDowngradeBuy ➝ NeutralLow
6/2/2020SVB LeerinkLower Price TargetMarket Perform$2.00 ➝ $1.00High
6/2/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$7.00 ➝ $2.00High
5/15/2020HC WainwrightReiterated RatingBuy$9.00Medium
5/14/2020Needham & Company LLCReiterated RatingBuy$7.00High
5/14/2020Royal Bank of CanadaReiterated RatingOutperform ➝ Market Perform$8.00Medium
3/13/2020Needham & Company LLCReiterated RatingBuyLow
1/21/2020G.ResearchDowngradeBuy ➝ SellHigh
1/21/2020GabelliDowngradeBuy ➝ SellHigh
12/11/2019Royal Bank of CanadaLower Price TargetPositive ➝ Outperform$14.00 ➝ $10.00High
12/11/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$4.00High
11/14/2019G.ResearchReiterated RatingBuyHigh
8/15/2019HC WainwrightReiterated RatingBuy$17.00Medium
6/21/2019HC WainwrightInitiated CoverageBuy ➝ Buy$17.00High
5/15/2019Royal Bank of CanadaLower Price TargetOutperform$17.00Low
3/25/2019Needham & Company LLCReiterated RatingBuy$20.00Low
11/14/2018Needham & Company LLCSet Price TargetBuy$20.00High
10/22/2018GabelliReiterated RatingBuyLow
8/14/2018Needham & Company LLCSet Price TargetBuy$20.00High
6/19/2018Royal Bank of CanadaInitiated CoverageOutperform$24.00High
6/19/2018Needham & Company LLCInitiated CoverageBuy$20.00High
6/19/2018SVB LeerinkInitiated CoverageOutperform$18.00High
6/19/2018GuggenheimInitiated CoverageBuy$21.00High
(Data available from 5/28/2017 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
10/30/2021
  • 3 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/28/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Iterum Therapeutics logo
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $0.22
Low: $0.22
High: $0.24

50 Day Range

MA: $0.29
Low: $0.19
High: $0.45

52 Week Range

Now: $0.22
Low: $0.19
High: $2.52

Volume

627,208 shs

Average Volume

1,369,961 shs

Market Capitalization

$40.89 million

P/E Ratio

11.16

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Iterum Therapeutics?

The following Wall Street analysts have issued research reports on Iterum Therapeutics in the last year: G.Research, Llc, Gabelli, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for ITRM.

What is the current price target for Iterum Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Iterum Therapeutics in the last year. Their average twelve-month price target is $0.70, suggesting a possible upside of 211.7%.
View the latest price targets for ITRM.

What is the current consensus analyst rating for Iterum Therapeutics?

Iterum Therapeutics currently has 1 sell rating and 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ITRM, but not buy more shares or sell existing shares.
View the latest ratings for ITRM.

How do I contact Iterum Therapeutics' investor relations team?

Iterum Therapeutics' physical mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company's listed phone number is (531) 903-8920 and its investor relations email address is [email protected] The official website for Iterum Therapeutics is www.iterumtx.com. Learn More about contacing Iterum Therapeutics investor relations.